Porton Advanced Solutions is a Suzhou, China-based CDMO dedicated to gene and cell therapy (GCT) development and manufacturing. The company provides an integrated GCT CDMO platform covering plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy and microbial vectors used for gene therapy. It currently operates a 40,000 sqft R&D and GMP production facility that has been in operation for over two years and has delivered plasmids, viruses and cell batches to sponsors. Porton Advanced plans to bring a 160,000 sqft commercial production facility online in late 2022/early 2023, bringing total PD, AD and GMP manufacturing to over 200,000 sqft. The firm intends to scale capacity to support AAV, oncolytic virus and mRNA CDMO capabilities, and will deploy proceeds to expand into different markets, invest in core manufacturing infrastructure and build global commercial operations. The company is led by CEO Dr. Wang Yangzhou.

Total raised

$80M

Funding rounds

1

Latest round

Series B

Latest activity

Aug 2022